November 18, 2016 - By Darrin Black · 0 Comments
MGC Diagnostics Corp (NASDAQ:MGCD) institutional sentiment decreased to 1 in 2016 Q2. Its down -0.67, from 1.67 in 2016Q1. The ratio dived, as 5 investment professionals increased or started new holdings, while 3 reduced and sold stock positions in MGC Diagnostics Corp. The investment professionals in our partner’s database now own: 896,896 shares, up from 887,021 shares in 2016Q1. Also, the number of investment professionals holding MGC Diagnostics Corp in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 2 Increased: 4 New Position: 1.
MGC Diagnostics Corporation is a medical technology company. The company has a market cap of $34.02 million. The Firm designs, markets and sells non-invasive cardiorespiratory diagnostic products. It has a 24.86 P/E ratio. The Firm operates in the manufacture and sale of cardiorespiratory diagnostic products segment.
About 7,148 shares traded hands or 225.35% up from the average. MGC Diagnostics Corp (NASDAQ:MGCD) has risen 35.32% since April 18, 2016 and is uptrending. It has outperformed by 30.89% the S&P500.
According to Zacks Investment Research, “MGC Diagnostics Corporation is a medical technology company dedicated to Cardio-Respiratory health solutions. It develops, manufactures and markets non-invasive diagnostic systems. The Company serves hospitals, university-based medical centers, medical clinics, physician offices, health and fitness clubs, weight loss clinics, and personal training studios. MGC Diagnostics Corporation, formerly known as Angeion Corporation, is based in Saint Paul, Minnesota.”
MGC Diagnostics Corporation, incorporated on March 10, 1987, is a medical technology company. The Firm designs, markets and sells non-invasive cardiorespiratory diagnostic products. The Firm operates in the manufacture and sale of cardiorespiratory diagnostic products segment. The Company’s product portfolio provides solutions for disease detection, integrated care, and wellness across the cardiorespiratory healthcare range. The Firm sells its products internationally through distributors and in the United States through a direct sales force targeting specialists located in hospitals, university medical centers, medical clinics, physician offices, pharmaceutical companies, medical device manufacturers and clinical research organizations (CROs). The Company’s cardiorespiratory diagnostic products measure flow and respiratory pressures and also analyzes the inhaled and exhaled gases, such as oxygen and carbon dioxide. The Firm offers its products in various categories, such as Pulmonary Function Products (PFT), Gas Exchange Testing Products, Cycle Ergometers and Treadmills, and Electronic Medical Records Interfaces.
More notable recent MGC Diagnostics Corp (NASDAQ:MGCD) news were published by: Prnewswire.com which released: “MGC Diagnostics Corporation Completes Acquisition of MediSoft SA” on August 01, 2014, also Prnewswire.com with their article: “MGC Diagnostics Corporation Announces Worldwide Exclusive Distribution …” published on March 19, 2013, Seekingalpha.com published: “MGC Diagnostics’s (MGCD) CEO Todd Austin on Q3 2016 Results – Earnings Call …” on September 07, 2016. More interesting news about MGC Diagnostics Corp (NASDAQ:MGCD) were released by: Tcbmag.com and their article: “Life Time Fitness Buys Assets From MGC Diagnostics For $1.24M” published on September 04, 2012 as well as Businesswire.com‘s news article titled: “IntriCon Appoints New Independent Director” with publication date: April 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black